# Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

> **NCT00859937** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 55 (actual)

## Conditions studied

- Malignant Salivary Gland Neoplasm
- Recurrent Salivary Gland Carcinoma
- Salivary Gland Adenoid Cystic Carcinoma
- Stage IV Major Salivary Gland Cancer AJCC v7

## Interventions

- **DRUG:** Dasatinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00859937
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-16
- **Primary completion:** 2013-01-30
- **Final completion:** —
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2018-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00859937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00859937, "Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00859937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*